# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0...
HC Wainwright & Co. analyst Joseph Pantginis downgrades VYNE Therapeutics (NASDAQ:VYNE) from Buy to Neutral.
Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75Nominally Statistically Significant Effec...